Category Archives: HIV/AIDS

PEPFAR: “One of the greatest global health achievements in recent history”

By on .

Data shows HIV investments in PEPFAR focus countries lowered mortality by 20 percent compared to non-focus countries Dr. Eran Bendavid of Stanford University set out to convince an audience at the 19th Conference of Retroviruses and Opportunistic Infections (CROI) Wednesday that assistance to Africa through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program […]

HIV incidence lowers as Medical Male Circumcision rates increase

By on .

The following is a guest blog post by HIV Medicine Association Executive Director Andrea Weddle, who is live blogging from the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. HIV incidence among non-Muslim men has decreased with greater uptake of voluntary medical male circumcision (MMC) in Uganda, according to data presented Tuesday at CROI. […]

AIDS-Free Generation may remain elusive goal

By on .

Dr. Dorothy Mbori-Ngacha from UNICEF presented a sobering picture of the potential to eliminate 90 percent of HIV infections among children by 2015—the goal established by UNAIDS and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program in June of 2011.  She outlined the four pillars of the achieving that goal at the 19th […]

Eye on Rwanda – successes and challenges in HIV testing and treatment

By on .

In many ways, Rwanda is a success story in terms of provision of services to people with HIV — just 18 years after 800,000 people were massacred in the country’s 1994 genocide. Anita Asiimwe, MD, MPH, of the Rwanda Biomedica Center in Kigali, drew a picture of what is seen on the ground for an […]

Poor adherence stopped study of PrEP in women

By on .

The following is a guest blog post by HIV Medicine Association Executive Director, Andrea Weddle, who is live blogging from the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) […]

HIV-infected infants benefit from immediate antiretroviral treatment

By on .

Results from two National Institutes of Health (NIH)-funded studies presented Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections underscore the importance of identifying and treating HIV-infected infants in the first year of life to protect their immune systems and to enable normal neurological development. Jintanat Ananworanich, MD, PhD, presented findings from the PREDICT […]

Loss to follow-up among HIV-infected pregnant women initiating HIV treatment is a huge challenge

By on .

On Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections, Dr. Landon Myer presented data from a study of 29,653 HIV infected women initiating antiretroviral therapy (ART) in the public sector in South Africa from 2002 to 2009.  The aim of the study was to compare loss to follow-up rates of pregnant women and […]

Improving on the results of CAPRISA 004: what’s genital tract inflammation got to do with it?

By on .

Investigators hinted at a way to improve upon the HIV prevention results achieved in the CAPRISA 004 one percent tenofovir vaginal microbicide study, which found a 39 percent protective benefit for women using the pre- and post- coital gel. Lead CAPRISA investigators Drs. Salim and Quarraisha Abdool Karim broached the subject during a thoughtful plenary […]

More data presented on the thorny issue of hormonal contraception and HIV transmission

By on .

Investigators presented more data dissecting the link between hormonal contraceptives and HIV transmission and disease progression Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle. Oral and Injectable Contraception use and risk of HIV acquisition among women, MIRA study Dr. Sandra McCoy reported on a secondary data analysis of hormonal contraception and […]

1% tenofovir microbicide gel with less glycerin proves safe and acceptable for rectal use

By on .

The Microbicides Trial Network  released promising results from its “MTN-007” Phase I safety and acceptability study, funded by the National Institutes of Health, looking at a new formulation of one percent tenofovir gel for rectal use Tuesday. The results were presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Earlier formulations […]